VivoSim LabsFRA:4OR 38 3-Year EBITDA Growth Rate is 54.10% as of Dec. 2025, which is 192% above its 10-year median of 18.50. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €11.36. The stock has 4 warning signs investors should review. Among 1,136 Biotechnology companies, VivoSim Labs ranks better than 87.68% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of VivoSim Labs was 54.10% per year. The lowest was -510.00% per year. And the median was 18.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
VivoSim Labs 3-Year EBITDA Growth Rate Related Terms
FRA:4OR vs SLXN, CDT, CLDI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, VivoSim Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.10% mean?
VivoSim Labs (FRA:4OR) has a 3-Year EBITDA Growth Rate of 54.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for VivoSim Labs and its competitors. This is 192% above median its historical median of 18.50. According to the industry distribution chart, VivoSim Labs ranks #140 out of 1136 companies in the Biotechnology industry, placing it in the top 12.3%.
Is VivoSim Labs' 3-Year EBITDA Growth Rate too high?
VivoSim Labs' current 3-Year EBITDA Growth Rate of 54.10% is 192% above median its 10-year median of 18.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. VivoSim Labs' value of 54.10% is 264.3% above this industry median. Based on the distribution chart, VivoSim Labs ranks #140 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 3-Year EBITDA Growth Rate compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #140 out of 1136 companies for 3-Year EBITDA Growth Rate. This places VivoSim Labs in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. VivoSim Labs' value of 54.10% is 264.3% above this benchmark. While the company's 10-year median is 18.50 vs. the industry median of 14.85, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current 3-Year EBITDA Growth Rate of 54.10% is 264.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for VivoSim Labs and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current 3-Year EBITDA Growth Rate is 54.10%, which is 192% above median its own 10-year median of 18.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 3-Year EBITDA Growth Rate of 54.10%. The stock's GF Value™ is €11.36, compared to a current price of €3.49 — trading 69.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 54.10%, which is 192% above median its 10-year median of 18.50 and 264.3% above the Biotechnology industry median of 14.85. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 3-Year EBITDA Growth Rate is 54.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 69.3% below its estimated GF Value™ of €11.36.
Key valuation signals for FRA:4OR:
3-Year EBITDA Growth Rate: 54.10% (192% above median its 10-year median of 18.50)
GF Value™: €11.36 vs. price of €3.49 (69.3% below fair value)
Industry Position: 264.3% above the Biotechnology median (#140 of 1136)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 